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1. Introduction 27 
Lung cancer is the leading cause of cancer-related mortality in the world. Non-small 28 
cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. By the time of 29 
diagnosis, the majority of patients are already at advanced stage of disease, and they can 30 
only benefit from a systemic palliative treatment. At present, the choice of pharmacological 31 
treatment for patients with metastatic disease is based on subject’s characteristics, on 32 
tumor histology and on genetic alterations (namely, Epidermal Growth Factor Receptor 33 
(EGFR) activating mutations, Anaplastic Lymphoma Kinase (ALK) and Proto-Oncogene 34 
Tyrosine-Protein Kinase reactive oxygen species (ROS-1) translocations), that are present 35 
in only about 20% of Western patients. While platinum-based chemotherapy is the 36 
standard of care for patients who do not exhibit EGFR activating mutations or other 37 
oncogene addictions, the first-line option for NSCLC patients who have tumors that harbor 38 
activating EGFR mutations is treatment with EGFR-tyrosine kinase inhibitors (EGFR-39 
TKIs), such as gefitinib, erlotinib or afatinib. [1] In these patients, EGFR-TKIs are better 40 
than chemotherapy as first-line treatment, in terms of progression-free survival (PFS), 41 
objective responses rates (ORR), safety profile and health-related quality of life.[2] 42 
Unfortunately, despite the initial efficacy of the treatments, drug resistance and disease 43 
progression almost always emerge. Although the combination of anti-angiogenic drugs 44 
and EGFR-TKIs (namely, the addition of the anti-VEGF bevacizumab to erlotinib) as first-45 
line therapy has produced a significant improvement in PFS, the occurrence of resistance 46 
remains the clinical rule even in patients treated with this combination.[3] 47 
Therefore, together with the identification of better treatments to use as first-line 48 
therapy of EGFR mutated NSCLC patients, another challenging open question regards the 49 
optimal management of those patients who develop resistance to first-line EGFR-TKIs. 50 
Different mechanisms can lead to acquired resistance to EGFR-TKIs: among the 51 
mechanisms described, the threonine to methionine point mutation in codon 790 of exon 52 
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20 (T790M), the human HER2 amplification, and the activation of secondary signaling 53 
such as MET amplification or phosphatidylinositol 3-kinase mutation. In addition, the 54 
transformation from NSCLC to SCLC or the epithelial-to-mesenchymal transition have 55 
been identified as further mechanisms of acquired resistance to EGFR-TKIs. Among these 56 
mechanisms, the T790M missense mutation is responsible for the acquired resistance in 57 
nearly 60% of patients.[4] Osimertinib, a third-generation EGFR-TKI, has shown high 58 
activity in EGFR T790M positive cases.[5] However, although exciting data of PFS and 59 
ORR have been reported in patients treated with osimertinib and other third-generation 60 
EGFR-TKIs, unfortunately acquired resistance occurs in all patients. Furthermore, the 61 
mechanisms of acquired resistance to third-generation EGFR-TKIs have not been 62 
completely understood and seems to be extremely various and heterogeneous, probably 63 
more complex than resistance to first- and second-generation EGFR-TKIs. [6] Thus 64 
nowadays, for T790M positive disease progressing after treatment with osimertinib, there 65 
are no other targeted agents approved. On the other hand, in T790M negative cases 66 
progressing after first-line EGFR-TKIs, no active biological drugs are available in clinical 67 
practice. [3] Therefore, chemotherapy remains the standard of care for patients with 68 
T790M positive tumor progressing after first-line EGFR-TKIs and second-line osimertinib, 69 
and for T790M negative patients progressing after first-line EGFR-TKIs. Immune 70 
checkpoint inhibitors (such as nivolumab, pembrolizumab, atezolizumab) are potential 71 
alternative salvage treatments in NSCLC, but subgroup analyses of randomized trials did 72 
not show a significant improvement in OS over chemotherapy in EGFR-mutated advanced 73 
NSCLC. [7] 74 
  75 
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2. Body of evidence 76 
To date, combination regimens of EGFR-TKIs and chemotherapy have no role in clinical 77 
practice. Several randomized phase III trials testing continuous daily administration of 78 
erlotinib or gefitinib, in combination with platinum-based chemotherapy doublets, as first-79 
line treatment of patients with advanced NSCLC, have failed to improve survival.[8,9]  The 80 
phase III TRIBUTE trial randomly assigned patients with advanced NSCLC to erlotinib or 81 
placebo combined with up to six cycles of carboplatin and paclitaxel, followed by 82 
maintenance monotherapy with erlotinib. Median survival was 10.6 months for patients 83 
treated with erlotinib and 10.5 months for placebo (hazard ratio, HR 0.99; 95% CI, 0.86 to 84 
1.16; P= .95).[8] The phase III INTACT 2 trial, randomized untreated patients with 85 
advanced NSCLC to receive chemotherapy with paclitaxel and carboplatin plus the EGFR-86 
TKI gefitinib at the dose of 500 mg/day, or gefitinib 250 mg/day, or placebo. There was no 87 
difference in overall survival (OS) (median, 8.7, 9.8, and 9.9 months for gefitinib 500 88 
mg/day, 250 mg/day, and placebo, respectively; P =0.64), TTP, or RR between arms.[9]  89 
Those negative clinical results were obtained in a population of patients unselected for 90 
EGFR mutational status, whereas exist evidences of PFS and OS improvement with first-91 
line concurrent combination therapies of the EGFR-TKI gefitinib plus platinum-based 92 
doublet chemotherapy (carboplatin/pemetrexed) compared to the sequential alternating 93 
administration of gefitinib and chemotherapy. [10] A phase III study comparing gefitinib 94 
with gefitinib plus concomitant carboplatin/pemetrexed in EGFR mutated NSCLC has 95 
recently concluded enrollment, and results are still not available. [11] 96 
Recently, Cheng et al reported the results of a randomized phase II trial comparing 97 
gefitinib alone vs. pemetrexed + gefitinib (continuous administration) as first-line therapy in 98 
195 East Asian patients with advanced nonsquamous NSCLC with activating EGFR 99 
mutations. [12] PFS, that was the primary endpoint, was significantly longer with 100 
pemetrexed plus gefitinib (median, 15.8 months) than with gefitinib (median, 10.9 months).  101 
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   Although the latter promising results underline that combination of chemotherapy 102 
and EGFR TKIs could perform better when tested in properly selected patients, it has been 103 
speculated that the previous negative clinical results - that were obtained in a population of 104 
patients unselected for EGFR mutational status -  were possibly due not only to 105 
inadequate selection of patients, but also to the cell-cycle timing interference. There is 106 
growing laboratory evidence of a possible sequence-dependent antagonism as a result of 107 
the well-known G1-phase arrest of tumor cells by EGFR-TKIs, which protect tumor cells 108 
from the cell cycle–specific cytotoxic agents.[13] Similarly, the attempt of combining 109 
continuous administration of EGFR-TKIs with platinum-based doublets chemotherapy after 110 
progression to EGFR-TKIs in patients affected by EGFR mutation positive NSCLC, did not 111 
produce significant improvement in patients’ outcome.[14] With this background, based on 112 
several preclinical data, some interest has grown for a strategy of sequencing and 113 
intercalating administration of chemotherapy and EGFR-TKIs. In particular, chemotherapy 114 
should be given after EGFR-TKI (pharmacodynamic separation), in order to avoid cell 115 
cycle-specific antagonism. Li et al. showed that interrupting erlotinib before the subsequent 116 
administration of pemetrexed in NSCLC cells should be the most effective sequence for 117 
combined treatment with these agents.[15] Interestingly, the synergism observed was 118 
independent from the mutational status of the EGFR or the intrinsic sensitivity to erlotinib.  119 
In another preclinical experience, La Monica et al demonstrated that simultaneous 120 
treatment with pemetrexed and gefitinib in NSCLC cell lines harboring a deletion in exon 121 
19 of EGFR gene enhanced cell growth inhibition and prevented the appearance of 122 
gefitinib resistance of mediated by T790M mutation, only when pemetrexed was the initial 123 
treatment. [16] 124 
Cheng et al. proved that the sequence of paclitaxel followed by gefitinib may be superior to 125 
other sequences in treating NSCLC cell lines; in fact, they demonstrated that exposure to 126 
paclitaxel in these cell lines resulted in an increased level of phosphorylated EGFR, and 127 
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this increase in phosphorylation was inhibited by subsequent exposure to gefitinib.[17] In 128 
addition, Bello et al., with the aim of identifying the optimal schedule for translation into the 129 
clinical setting, demonstrated the efficacy of different treatment schedules involving 130 
vinorelbine and gefitinib in NSCLC cell lines (either with the L858R/T790M EGFR mutation 131 
or wild-type).[18] Tsai et al., using a panel of 12 NSCLC cell lines that had no sensitizing 132 
EGFR mutations (SEM), demonstrated synergism in combining gefitinib with 133 
antimicrotubule agents.[19] The same authors tested six different gefitinib–drug 134 
combinations in 15 NSCLC cell lines with and without SEMs. They showed that in the 135 
EGFR wild-type NSCLC cells, gefitinib created synergism when treated in combination 136 
with pemetrexed or other citotoxic agents (antagonism with cisplatin). Instead, NSCLC 137 
cells with SEMs seemed be more chemo-refractory and showed a tendency toward 138 
consistent antagonism when gefitinib was used concurrently with chemotherapy. They 139 
concluded that concomitant administration of EGFR-TKI and chemotherapeutic agents is 140 
not  a good treatment strategy for NSCLC patients harboring SEMs, and suggested a 141 
strategy of intercalated administration of same agents.[20] 142 
 Based on those encouraging preclinical evidence, the intercalated administration of 143 
EGFR-TKIs (in particular gefitinib or erlotinib), and chemotherapy in patients with 144 
advanced NSCLC has been investigated in phase II and phase III, randomized and non-145 
randomized, clinical trials.[21, 22, 23, 24] For instance, a phase ΙΙ study evaluated the 146 
administration of cisplatin and docetaxel based chemotherapy plus intercalated gefitinib for 147 
advanced NSCLC EGFR mutated patients. [24] The primary endpoint of the study was the 148 
two–year PFS rate. The 1–, 2–, and 3–year estimated PFS rates were 59.4%, 37.5%, and 149 
33.8%, respectively, and the median PFS time was 19.2 months. The 1–, 2–, and 3–year 150 
estimated survival rates were 90.0%, 82.9%, and 62.4%, respectively, and the median 151 
survival time had not been reached at the time of analysis. A recent meta-analysis of 152 
randomized trials (RCTs) [21] showed that this therapeutic strategy might be effective in 153 
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the treatment of advanced NSCLC patients, not selected by EGFR mutational status. 154 
According to the results of this meta-analysis, the intercalated schedule is associated with 155 
a significant improvement in OS (hazard ratio [HR], 0.82; 95% confidence interval [CI], 156 
0.71-0.95; P = .01), PFS (HR, 0.60; 95% CI, 0.53-0.68; P < .00001), and objective 157 
response rate (ORR; odds ratio [OR], 2.70; 95% CI, 2.08-3.49; P < .00001), compared to 158 
chemotherapy alone. Notably, the RCTs considered in this meta-analysis were 159 
heterogeneous for the EGFR-TKI used, for the type of chemotherapy (platinum-based or 160 
single-agent), for the line of treatment (first-line versus pretreated patients), for the  EGFR 161 
mutational status (which was known only in 43% of the patients included) and for the 162 
clinical characteristics of eligible patients (in terms of ethnicity, age, PS, smoking history 163 
and tumor histology). Subgroup analyses suggested that in patients with tumors harboring 164 
EGFR-activating mutations, there was a significant benefit in PFS (HR, 0.24; 95% CI, 165 
0.16-0.37; P < .00001) and ORR (OR, 11.59; 95% CI, 5.54-24.25; P < .00001) with the 166 
addition of intercalated EGFR-TKI to chemotherapy.  167 
  168 
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3. Expert opinion 169 
Unfortunately, the results of the meta-analysis[21] document the efficacy of the 170 
combination compared to chemotherapy, while there is no robust evidence to define the 171 
relative efficacy of the intercalated combination compared to single-agent EGFR-TKIs. 172 
However, the addition of an EGFR-TKI to chemotherapy could be of interest in the 173 
treatment of patients with unknown EGFR mutational status: this strategy should be tested 174 
in dedicated prospective trials to better define its role, although the lack of information 175 
about EGFR mutational status should be no longer acceptable in modern clinical practice. 176 
As for patients with EGFR mutation, who are candidates to receive chemotherapy as 177 
second-line (if T790M negative) or further line of therapy (if T790M positive), the results of 178 
the meta-analysis are not directly applicable, because most patients included in the trials 179 
considered were treatment-naïve and were not pre-treated with an EGFR-TKI. However, 180 
despite the occurrence of molecular changes associated with resistance, the original 181 
EGFR mutation remains detectable at the onset of resistance, and this finding suggests 182 
that EGFR should be considered a principal driver for progressing neoplastic clones even 183 
after disease progression. [19] As a consequence, on the basis of the preclinical data 184 
reported and considering the positive results obtained in response rate and survival 185 
endpoints with the intercalated combination of EGFR-TKI and chemotherapy in NSCLC, 186 
we suggest that intercalated schedule could represent not only a promising way to delay 187 
the development of treatment resistance, but also a potentially active strategy after EGFR-188 
TKI resistance development.[23] Of course, only well designed randomized trials may help 189 
in verifying this hypothesis.  190 
In conclusion, dedicated prospective studies are needed to assess the impact of the 191 
intercalated regimen as a weapon to delay or revert the onset of EGFR-TKI resistance in 192 
NSCLC patients. Currently, several different clinical trials regarding intercalated EGFR-TKI 193 
and chemotherapy in advanced NSCLC are ongoing: both single-arm and randomized 194 
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studies, regarding first- or subsequent lines setting, with heterogeneous treatment 195 
administered [Table 1]. Some of these trials will help to better define the role of 196 
intercalated administration of EGFR-TKIs and chemotherapy.  197 
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Table 1. Ongoing trials with intercalated EGFR-TKI and chemotherapy in patients with advanced NSCLC 
 
Clinicaltrials.gov  
Identifier 
 
Phase 
 
Patients 
 
Control arm 
 
Experimental arm 
 
Primary 
endpoint 
 
Accrual* 
 
NCT02031601 
 
III 
EGFR mutated, 
first-line treatment 
Single-agent TKI 
(erlotinib or gefitinib or 
icotinib) 
Chemotherapy (docetaxel or 
pemetrexed plus platinum), day 1, plus 
TKI (erlotinib or gefitinib or icotinib), 
days 2-15, every 3 weeks 
PFS Recruiting 
 
NCT02064491 
 
II 
 
EGFR mutated, 
progressed after 
first-line EGFR-TKI 
Chemotherapy (cisplatin 
or carboplatin plus 
docetaxel or paclitaxel 
or pemetrexed), day 1 
every 3 weeks 
Chemotherapy (same as in control 
arm), day 1, plus intercalated erlotinib, 
every 3 weeks 
PFS Completed 
 
NCT02775006 
 
III 
 
EGFR wild type, 
progressedafter one 
platinum- containing 
regimen 
Chemotherapy 
(docetaxel), day 1 every 
3 weeks 
Chemotherapy (docetaxel), day 
1,  plus intercalated erlotinib,  
days 2-16 
every 3 weeks 
PFS Recruiting 
 
NCT03151161 
 
II 
 
EGFR mutated, 
first-line treatment 
Chemotherapy 
(carboplatin plus 
pemetrexed), day  1 
every 3 weeks 
Chemotherapy (carboplatin plus 
pemetrexed), day 1, plus intercalated 
icotinib, days 2-15, every 3 weeks 
Response 
rate 
 
Recruiting 
UMIN000020242 III EGFR mutated, first-line treatment 
Single-agent TKI 
Gefitinib 
Gefitinib on days 1-56 ,cisplatin and 
pemetrexed on days 71, 92, 113 and 
again Gefitinib on day 134 
OS Recruiting 
 
EGFR: Epidermal Growth Factor Receptor; TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; PFS: progression-free survival;  
*as reported in ClinicalTrials.gov and UMIN-CTR Clinical Trial on July 2, 2017,  
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